Zimmer Biomet Holdings (ZBH) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Zimmer Biomet (ZBH) PT Raised to $117 at Truist Securities
October 31, 2024 12:37 PM EDTTruist Securities analyst Richard Newitter raised the price target on Zimmer Biomet (NYSE: ZBH) to $117.00 (from $112.00) while maintaining a Hold rating.
The analyst comments "ZBH's 3Q cc rev beat offset by ~90bps op margin miss; in-line EPS benefited from non-operating items and... More
Oppenheimer Reiterates Outperform Rating on Zimmer Biomet (ZBH)
October 30, 2024 4:28 PM EDTOppenheimer analyst Steven Lichtman reiterated an Outperform rating and $135.00 price target on Zimmer Biomet (NYSE: ZBH).
The analyst comments "3Q24 sales of $1.824B (+4.1% constant-currency) outpaced our/Street's $1.791B/$1.795B on less ERP headwind than expected and better than expected underlying performance, particularly in SET. Knees... More
